ADVERTISEMENT
Abstracts
P025
Evaluating the Safety and Efficacy of the BeEAM (Bendamustine, Etoposide, Cytarabine & Melphalan) Conditioning Regimen for Autologous Stem Cell Transplant in Patients with Relapsed Lymphomas; A Retrospective Chart Review
Introduction:
The BEAM (BCNU/Carmustine, Etoposide, Cytarabine, Melphalan) regimen has historically been favored as the conditioning treatment of choice for patients with relapsed or refractory lymphoma undergoing autologous stem cell transplant (ASCT). However, a recent worldwide shortage of Carmustine (BCNU), as well as concerns regarding the long-term risk of idiopathic lung disease has pushed clinicians to search for alternatives. Bendamustine, as part of the BeEAM regimen (Bendamustine, Etoposide, Cytarabine, Melphalan) has shown to be a promising substitute. We sought to evaluate the safety and efficacy of BeEAM at our institution.
Methods:
This retrospective single-center observational chart review included all patients with refractory or relapsed lymphoma who underwent autologous stem cell transplantation with the BeEAM (Bendamustine, Etoposide, Cytarabine & Melphalan) high-dose chemotherapy conditioning regimen between June 2019 and January 2022 at the Jewish General Hospital in Montreal. Chemotherapy-associated toxicities where graded based on version 5 of the Common Terminology Criteria for Adverse Event (CTCAE v5).
Results:
During the two-and-a-half-year study period, a total of 19 patients were included. After a median follow-up of 14 months, progression-free survival (PFS) and overall survival (OS) were 68.4% and 84.2%, respectively. A total of 2 deaths (10.5%) occurred within 100‚Äâdays from transplant, however, only 1 was deemed to be transplant-related (TRM of 5.3%). Grade III-IV diarrhea was the most prevalent Bendamustine-related toxicity, with 52.6% of patients developing it. We reported acceptable rates of grade III-IV mucositis (31.2%), nausea/vomiting (47.4% & 42.1%, respectively) and acute kidney injury (26.3%).
Discussion:
At our institution, the experience with the BeEAM conditioning regimen yielded an acceptable toxicity profile and comparable efficacy to BEAM, based on a reported response rates in the literature.
The BEAM (BCNU/Carmustine, Etoposide, Cytarabine, Melphalan) regimen has historically been favored as the conditioning treatment of choice for patients with relapsed or refractory lymphoma undergoing autologous stem cell transplant (ASCT). However, a recent worldwide shortage of Carmustine (BCNU), as well as concerns regarding the long-term risk of idiopathic lung disease has pushed clinicians to search for alternatives. Bendamustine, as part of the BeEAM regimen (Bendamustine, Etoposide, Cytarabine, Melphalan) has shown to be a promising substitute. We sought to evaluate the safety and efficacy of BeEAM at our institution.
Methods:
This retrospective single-center observational chart review included all patients with refractory or relapsed lymphoma who underwent autologous stem cell transplantation with the BeEAM (Bendamustine, Etoposide, Cytarabine & Melphalan) high-dose chemotherapy conditioning regimen between June 2019 and January 2022 at the Jewish General Hospital in Montreal. Chemotherapy-associated toxicities where graded based on version 5 of the Common Terminology Criteria for Adverse Event (CTCAE v5).
Results:
During the two-and-a-half-year study period, a total of 19 patients were included. After a median follow-up of 14 months, progression-free survival (PFS) and overall survival (OS) were 68.4% and 84.2%, respectively. A total of 2 deaths (10.5%) occurred within 100‚Äâdays from transplant, however, only 1 was deemed to be transplant-related (TRM of 5.3%). Grade III-IV diarrhea was the most prevalent Bendamustine-related toxicity, with 52.6% of patients developing it. We reported acceptable rates of grade III-IV mucositis (31.2%), nausea/vomiting (47.4% & 42.1%, respectively) and acute kidney injury (26.3%).
Discussion:
At our institution, the experience with the BeEAM conditioning regimen yielded an acceptable toxicity profile and comparable efficacy to BEAM, based on a reported response rates in the literature.
Publisher
John Wiley & Sons; Hoboken, USA
Source Journal
American Journal of Hematology
2022 Wiley Periodicals LLC.
